Anixa Biosciences Inc ANIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANIX is a good fit for your portfolio.
News
-
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
-
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
-
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
-
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
-
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Trading Information
- Previous Close Price
- $3.18
- Day Range
- $2.94–3.32
- 52-Week Range
- $2.75–5.13
- Bid/Ask
- $3.00 / $3.01
- Market Cap
- $95.06 Mil
- Volume/Avg
- 251,933 / 121,156
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 441.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.anixa.com
Comparables
Valuation
|
Metric
|
ANIX
|
ANAB
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.85 | 5.82 | 4.82 |
Price/Sales | 441.48 | 30.24 | 260.58 |
Price/Cash Flow | — | — | — |
Price/Earnings
ANIX
ANAB
CLDX
Financial Strength
|
Metric
|
ANIX
|
ANAB
|
CLDX
|
|---|---|---|---|
Quick Ratio | 14.57 | 10.62 | 13.69 |
Current Ratio | 15.19 | 10.87 | 13.87 |
Interest Coverage | — | −9.09 | — |
Quick Ratio
ANIX
ANAB
CLDX
Profitability
|
Metric
|
ANIX
|
ANAB
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −23.59% | −23.50% | −30.49% |
Return on Equity (Normalized) | −24.38% | −75.96% | −33.19% |
Return on Invested Capital (Normalized) | −29.89% | −68.56% | −32.85% |
Return on Assets
ANIX
ANAB
CLDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gskfmsgln | Cjy | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hqxvsdgfx | Ztjstv | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cqlhztnfp | Txlhy | $97.8 Bil | |
MRNA
| Moderna Inc | Bgnqvzy | Vssmf | $38.8 Bil | |
ARGX
| argenx SE ADR | Whlqdrzl | Fsrv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jqzvgsyj | Qxt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kqgcqgq | Rkkxqd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hzbvqjvhg | Ldcqnrn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nflbrfntb | Ktkztv | $12.5 Bil | |
INCY
| Incyte Corp | Kxswnxzw | Mgyfr | $11.5 Bil |